Hematology Frontier

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine presented multiple innovative studies in the field of hematopoietic stem cell transplantation. These studies covered in-depth analyses of HLA evolutionary divergence (HED), post-transplant maintenance with epigenetic regulatory agents, and other cutting-edge topics, highlighting an integrated translational medicine strategy aimed at addressing key clinical challenges, comprehensively improving transplant outcomes, and enhancing long-term patient survival and quality of life. During the meeting, Hematology Frontier invited Professor Zhao Yanmin from the First Affiliated Hospital of Zhejiang University School of Medicine to systematically interpret the team’s core research achievements, elucidate their clinical value, and discuss future development directions, providing valuable insights for both academic research and clinical practice.

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando, USA. As the world’s largest and most influential international academic conference in the field of hematology, the ASH Annual Meeting attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research. At this year’s meeting, a study led by Professor Sun Ruijuan from Lu Daopei Hospital was selected for poster presentation, focusing on the clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia, providing important insights for the treatment of this challenging patient population. Hematology Frontier invited Professor Sun to share the details of this study for academic exchange.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, showcasing the latest global advances in hematology. Multiple studies…

From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together leading experts worldwide to present the latest breakthroughs in…

Previous collaborative studies between the European Society for Blood and Marrow Transplantation (EBMT) and Prof. He Huang’s team have demonstrated that haploidentical hematopoietic stem cell transplantation (HAPLO-HSCT) can confer clinical…

At the 67th Annual Meeting of the American Society of Hematology (ASH), Prof. Ou Bai and her team from The First Hospital of Jilin University presented multiple impactful studies. Two…

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.

In recent years, with the rapid development of precision genomics, hereditary predisposition genes have gained increasing attention for their clinical value in the diagnosis and treatment of hematologic malignancies. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Li Zhihui from Beijing Gaobo Boren Hospital was selected for oral presentation, systematically evaluating the impact of hereditary predisposition genes on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor selection. Hematology Frontier invited Professor Li for an in-depth interpretation of this study and its implications for clinical practice.

At the annual meeting of the American Society of Hematology (ASH), research in FLT3-ITD acute myeloid leukemia (AML) delivered important advances for clinical practice. Notably, the latest findings from the QUIWI study series further revealed that, among FLT3-ITD–negative patients, FLT3 ligand (FL) levels and microclonal status can help identify prognostic heterogeneity, offering a new paradigm for dynamic monitoring and risk-adapted intervention. On site, Oncology Frontier · Hematology Frontier invited Professor Wang Jianxiang from the Institute of Hematology, Chinese Academy of Medical Sciences, to discuss key advances, including the prognostic value of FLT3 ligand, the clinical relevance of microclonal detection, and the therapeutic potential of quizartinib, with the aim of building a comprehensive FLT3-marker–based management framework to advance AML care toward greater precision and dynamism.

At this year’s American Society of Hematology (ASH) Annual Meeting, advances in FLT3-ITD acute myeloid leukemia (AML) delivered important clinical insights. From evolving treatment paradigms to optimized maintenance strategies and breakthroughs in targeted therapy, these studies consistently centered on precision medicine, driving care toward greater efficiency and individualization. On site at ASH, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to interpret key developments in dynamic management, maintenance therapy, and targeted drug application in FLT3-ITD AML, with the aim of informing clinical decision-making.